|
Endometrial Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.
|
23104009 |
2012 |
|
Endometrial Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.
|
23104009 |
2012 |
|
Lupus Erythematosus, Discoid
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The Y-located testis-specific protein Y-encoded (TSPY) and its X-homologue TSPX originated from the same ancestral gene, but act as a proto-oncogene and a tumor suppressor gene, respectively.
|
29974883 |
2020 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The C-terminal acidic domain (CAD) of TSPX is crucial for the tumor suppressor functions, such as inhibition of cyclin B/CDK1 phosphorylation and androgen receptor transactivation.
|
30863497 |
2019 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The gonadoblastoma gene, testis-specific protein Y-encoded (TSPY), on the Y chromosome and its X-homologue, TSPX, are cell cycle regulators and function as a proto-oncogene and a tumor suppressor respectively in human oncogenesis.
|
28169398 |
2017 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
CTCL are rare neoplasms.Optimal care requires integrated use of diagnostic and treatment modalities spanning multiple specialties.
|
27998183 |
2017 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Since mutation and/or epigenetic repression of X-located tumor suppressor gene(s) could significantly predispose males to human cancers, our data suggest that TSPX-induced HBx degradation could play key role(s) in hepatocarcinogenesis among HBV-infected HCC patients.
|
21829568 |
2011 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
We investigated the arrangement of Ig and T-cell receptor (TCR) genes, together with the involvement of several oncogenes and the tumor-suppressor gene p53, in a panel of primary cutaneous B- and T-cell lymphomas (CBCLs and CTCLs).
|
7579411 |
1995 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
It is now known that CTCL is a monoclonal T-cell disorder like other T-cell neoplasms and that the same tumor clone is generally present in all sites of tissue involvement.
|
8045035 |
1994 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
All the positive cases were examples of the plaque or tumor stages of CTCL.
|
2297046 |
1990 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Battle of the sexes: contrasting roles of testis-specific protein Y-encoded (TSPY) and TSPX in human oncogenesis.
|
29974883 |
2020 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Datamining of transcriptomes of prostate cancer specimens in the Cancer Genome Atlas (TCGA) dataset confirmed the negative correlation between the expression level of TSPX and those of MYC and MYB in clinical prostate cancer, thereby supporting the hypothesis that the CAD of TSPX plays an important role in suppression of cancer-drivers/oncogenes in prostatic oncogenesis.
|
30863497 |
2019 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
The gonadoblastoma gene, testis-specific protein Y-encoded (TSPY), on the Y chromosome and its X-homologue, TSPX, are cell cycle regulators and function as a proto-oncogene and a tumor suppressor respectively in human oncogenesis.
|
28169398 |
2017 |
|
Carcinogenesis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
The contrasting properties of TSPY and TSPX suggest that somatic cancers, such as intracranial germ cell tumors, melanoma, and hepatocellular carcinoma, with detectable TSPY expression could exhibit sexual dimorphisms in the initiation and/or progression of the respective oncogenesis.
|
19306348 |
2009 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Thus, the results indicate that a significant high level of telomerase activity and shortened telomere length frequently occur in T cells of patients with CTCL and may reflect tumorigenesis.
|
11589730 |
2001 |
|
Mycosis Fungoides
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Patients with early stage Mycosis Fungoides (MF) variant of CTCL may experience an indolent course over decades, whereas patients with advanced MF and Sézary Syndrome (SS) disease at diagnosis, often succumb within 5 years.
|
30221071 |
2018 |
|
Mycosis Fungoides
|
0.040 |
Biomarker
|
group |
BEFREE |
CTCLs were divided into 4 subgroups: α/β CTCL (n = 3), nasal type CTCL (n = 0), γ/δ CTCL (n = 10) and mycosis fungoides (n = 10).
|
28218382 |
2018 |
|
Mycosis Fungoides
|
0.040 |
Biomarker
|
group |
BEFREE |
Our data are of clinical value and indicate that the bortezomib/methotrexate combinational therapy has an inferior impact on the apoptosis of CTCL compared to monotherapy, with bortezomib presenting as the most efficient treatment option for SS and methotrexate for MF.
|
28107479 |
2017 |
|
Mycosis Fungoides
|
0.040 |
Biomarker
|
group |
BEFREE |
In silico analysis of pre-existing metagenomics datasets then revealed closely related parvovirus genomes in skin biopsies from patients with epidermotropic cutaneous T-cell lymphoma (CTCL or mycosis fungoides).
|
27393975 |
2016 |
|
Sezary Syndrome
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Patients with early stage Mycosis Fungoides (MF) variant of CTCL may experience an indolent course over decades, whereas patients with advanced MF and Sézary Syndrome (SS) disease at diagnosis, often succumb within 5 years.
|
30221071 |
2018 |
|
T-Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
B-cell lymphomas (CBCLs; n = 86) and T-cell lymphomas (CTCLs; n = 23) were analyzed separately.
|
28218382 |
2018 |
|
Sezary Syndrome
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our data are of clinical value and indicate that the bortezomib/methotrexate combinational therapy has an inferior impact on the apoptosis of CTCL compared to monotherapy, with bortezomib presenting as the most efficient treatment option for SS and methotrexate for MF.
|
28107479 |
2017 |
|
Lymphoma, T-Cell, Cutaneous
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In silico analysis of pre-existing metagenomics datasets then revealed closely related parvovirus genomes in skin biopsies from patients with epidermotropic cutaneous T-cell lymphoma (CTCL or mycosis fungoides).
|
27393975 |
2016 |
|
Congenital dyserythropoietic anemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
The first CDA partly accounted for genetically has been CDA 1, through the discovery in 2002 of the gene responsible, CDAN1, encoding codanin-1.
|
21378561 |
2011 |